Michel Spagnol – President and CEO, Novasep, France

Michel Spagnol, chairman and CEO of Novasep, a robust French CDMO, shares his insights on the key global trends that are shaping today’s CMDO sector – particularly the emerging significance of biopharmaceuticals and gene therapies. Spagnol goes on to elaborate on his strategy to revitalize Novasep’s organizational structure and position the company as a reference partner of choice within the biologics space.  
Overall, biologics at large are going to be the shapers of the industry moving forward, and I am glad to say our company took this path several years ago
Become a PharmaBoardroom Member for free to access this content
Join the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Already a member? Sign In

Related Interviews

Latest Report